FDA Accepts Verastem NDA for Priority Review, Stocks Up 20% (Update)


US Food and Drug Administration (FDA) Headquarters

Grandbrothers

Verastem (NASDAQ:VSTM) shares rose 20% in after-hours trading on news that the FDA accepted for priority review the company's new drug application for accelerated approval of its ovarian cancer drugs avutometinib and defactinib, with



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *